Histotripsy Technology Addresses Breast Cancer and Liver Cancer in Hong Kong Public Hospitals

Histotripsy Technology Overview

Histotripsy is a revolutionary non-invasive treatment that utilizes high-intensity ultrasound waves to precisely disrupt and liquefy targeted tumor cells without harming surrounding healthy tissue. As public hospitals explore the potential of this technology, the implications for cancer treatment are significant.

Impact of Li Ka-shing's Donation

In a groundbreaking move, Li Ka-shing donated state-of-the-art histotripsy machines to the University of Hong Kong and the Chinese University of Hong Kong (CUHK) last year. This donation, which includes devices valued at approximately US$3 million, has led to their listing under the voluntary Medical Device Administration Control System (MDACS) in Hong Kong.

Current Status in Healthcare Facilities

The Hospital Authority confirmed that while inclusion in the MDACS is vital for device procurement, it does not guarantee that public hospitals will purchase every listed device. Their decision will consider criteria like quality, safety, and technical support.

Clinical Trials and Future Perspectives

Ongoing clinical trials aim to assess the efficacy of histotripsy in liver cancer treatment. Meanwhile, the CUHK has expressed interest in exploring its application for breast cancer treatment.

Conclusion and Next Steps

While the potential benefits of histotripsy are compelling, Hong Kong’s healthcare system continues to evaluate its integration into public health services. Ongoing discussions regarding access to such technologies remain vital for the future of cancer care in the region.